Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04655976 · ClinicalTrials.gov registry record · Phase 3
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
A Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 3
- Development phase
- 758
- Enrollment target
- 20
- Study locations
NCT04655976: Active Phase 3 study of Lung Cancer, Non-Small Cell, sponsored by GlaxoSmithKline.
NCT04655976 is a Phase 3 study of Lung Cancer, Non-Small Cell that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 758 participants, above the 408-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04655976, a Phase 3 study of Lung Cancer, Non-Small Cell, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 758 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Primary Outcome
OS is defined as the time from the date of randomization to the date of death due to any cause.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Dostarlimab
- BIOLOGICAL Cobolimab
Study Locations (20)
New York
- GSK Investigational Site - Mineola
- GSK Investigational Site - New York
- GSK Investigational Site - White Plains
Other
- GSK Investigational Site - Buenos Aires
- GSK Investigational Site - Cipoletti Rio Negro
- GSK Investigational Site - Ciudad Autonoma de Buenos Aire
California
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - Walnut Creek
Pennsylvania
- GSK Investigational Site - Pittsburgh
- GSK Investigational Site - Pittsburgh
Connecticut
- GSK Investigational Site - Norwich
District of Columbia
- GSK Investigational Site - Washington D.C.
Hawaii
- GSK Investigational Site - Honolulu
Iowa
- GSK Investigational Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 758 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2027-03-30 |
| Phase | Phase 3 |
What the registry record for NCT04655976 still lists
NCT04655976 is an interventional study that assigns participants to a tested intervention. The registered 758 participants enrollment target is mid-sized for trials with a published cap, above the 408-participant average among 16 other Lung Cancer, Non-Small Cell trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Lung Cancer, Non-Small Cell appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT04655976 names 20 study sites across 14 states, led by New York, Other, California.
Frequently Asked Questions
What is clinical trial NCT04655976 about?
NCT04655976 is a clinical study titled "Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy". This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
What is the current status of trial NCT04655976?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 758 participants. The study started on 2020-12-08. Estimated completion is 2027-03-30.
What conditions does trial NCT04655976 study?
This clinical trial studies the following conditions: Lung Cancer, Non-Small Cell.
What interventions are being tested in trial NCT04655976?
The interventions under investigation include: Docetaxel (DRUG), Dostarlimab (BIOLOGICAL), Cobolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04655976?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04655976 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Hawaii, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Non-Small Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04655976's enrollment target sits among peer trials
758 3rd of 16 higher than 14 of 16 other Lung Cancer, Non-Small Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer, Non-Small Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 3
-
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
COMPLETED · Phase 3
-
Engagement of Veterans With Lung Cancer
RECRUITING · NA
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02089607 · 760 participants · NA
CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft
- NCT04073706 · 760 participants · Phase 3
Sentinel Node Biopsy in Endometrial Cancer
- NCT05129228 · 760 participants · NA
Optical Coherence Tomography of the Saphenous Vein Graft
- NCT05787821 · 760 participants
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI